CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Louisville, Kentucky, United States and 43 other locations
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...
Phase 2
Louisville, Kentucky, United States and 49 other locations
and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...
Phase 2
Louisville, Kentucky, United States and 46 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Louisville, Kentucky, United States and 209 other locations
the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung...
Phase 1, Phase 2
Louisville, Kentucky, United States and 8 other locations
The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of this study are to see how safe an...
Phase 2
Louisville, Kentucky, United States and 54 other locations
docetaxel in patients with advanced or metastasized non-small cell lung cancer (NSCLC) and unresectable NSCLC after chemoradiothera...
Phase 1
Louisville, Kentucky, United States and 33 other locations
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...
Phase 1
Louisville, Kentucky, United States of America and 20 other locations
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic...
Phase 2
Louisville, Kentucky, United States and 25 other locations
overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung...
Phase 2
Louisville, Kentucky, United States and 126 other locations
Clinical trials
Research sites
Resources
Legal